Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Oct, 2016 | Pages:
442 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Relapsed Acute Myeloid Leukemia - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Relapsed Acute Myeloid Leukemia - Pipeline Review, H2 2016, provides an overview of the Relapsed Acute Myeloid Leukemia (Oncology) pipeline landscape. Return of acute myeloid leukemia (AML) cells in the marrow and a decrease in normal blood cells after remission is called a relapsed acute myeloid leukemia. Signs and symptoms includes pale skin, swollen gums, minor infections, such as perianal sores, loss of appetite and weight loss and aches or discomfort in bones or joints such as knees, hips or shoulders. Predisposing factors include age, history of other blood cancers or disorders, genetic disorder and past chemotherapy or radiation treatments. Treatment includes chemotherapy with the same or different drugs used previously during treatment. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Relapsed Acute Myeloid Leukemia - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Relapsed Acute Myeloid Leukemia (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Relapsed Acute Myeloid Leukemia (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Relapsed Acute Myeloid Leukemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 5, 35, 35, 1, 3 and 1 respectively for Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 3, 6 and 2 molecules, respectively for Relapsed Acute Myeloid Leukemia. Relapsed Acute Myeloid Leukemia (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Relapsed Acute Myeloid Leukemia (Oncology). - The pipeline guide reviews pipeline therapeutics for Relapsed Acute Myeloid Leukemia (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Relapsed Acute Myeloid Leukemia (Oncology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Relapsed Acute Myeloid Leukemia (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Relapsed Acute Myeloid Leukemia (Oncology) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Relapsed Acute Myeloid Leukemia (Oncology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Relapsed Acute Myeloid Leukemia (Oncology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 Introduction 5 Relapsed Acute Myeloid Leukemia Overview 6 Therapeutics Development 7 Relapsed Acute Myeloid Leukemia - Therapeutics under Development by Companies 9 Relapsed Acute Myeloid Leukemia - Therapeutics under Investigation by Universities/Institutes 13 Relapsed Acute Myeloid Leukemia - Pipeline Products Glance 14 Relapsed Acute Myeloid Leukemia - Products under Development by Companies 17 Relapsed Acute Myeloid Leukemia - Products under Investigation by Universities/Institutes 22 Relapsed Acute Myeloid Leukemia - Companies Involved in Therapeutics Development 23 Relapsed Acute Myeloid Leukemia - Therapeutics Assessment 80 Drug Profiles 100 Relapsed Acute Myeloid Leukemia - Dormant Projects 414 Relapsed Acute Myeloid Leukemia - Discontinued Products 416 Relapsed Acute Myeloid Leukemia - Product Development Milestones 417 Appendix 430
List of Tables
Number of Products under Development for Relapsed Acute Myeloid Leukemia, H2 2016 18 Number of Products under Development for Relapsed Acute Myeloid Leukemia - Comparative Analysis, H2 2016 19 Number of Products under Development by Companies, H2 2016 20 Number of Products under Development by Companies, H2 2016 (Contd..1) 21 Number of Products under Development by Companies, H2 2016 (Contd..2) 22 Number of Products under Development by Companies, H2 2016 (Contd..3) 23 Number of Products under Investigation by Universities/Institutes, H2 2016 24 Comparative Analysis by Late Stage Development, H2 2016 25 Comparative Analysis by Clinical Stage Development, H2 2016 26 Comparative Analysis by Early Stage Development, H2 2016 27 Products under Development by Companies, H2 2016 28 Products under Development by Companies, H2 2016 (Contd..1) 29 Products under Development by Companies, H2 2016 (Contd..2) 30 Products under Development by Companies, H2 2016 (Contd..3) 31 Products under Development by Companies, H2 2016 (Contd..4) 32 Products under Investigation by Universities/Institutes, H2 2016 33 Relapsed Acute Myeloid Leukemia - Pipeline by 4SC AG, H2 2016 34 Relapsed Acute Myeloid Leukemia - Pipeline by AbbVie Inc, H2 2016 35 Relapsed Acute Myeloid Leukemia - Pipeline by Actinium Pharmaceuticals, Inc., H2 2016 36 Relapsed Acute Myeloid Leukemia - Pipeline by ADC Therapeutics Sarl, H2 2016 37 Relapsed Acute Myeloid Leukemia - Pipeline by Aeglea BioTherapeutics, Inc., H2 2016 38 Relapsed Acute Myeloid Leukemia - Pipeline by Agios Pharmaceuticals, Inc., H2 2016 39 Relapsed Acute Myeloid Leukemia - Pipeline by Aileron Therapeutics, Inc., H2 2016 40 Relapsed Acute Myeloid Leukemia - Pipeline by Amgen Inc., H2 2016 41 Relapsed Acute Myeloid Leukemia - Pipeline by Arog Pharmaceuticals, Inc., H2 2016 42 Relapsed Acute Myeloid Leukemia - Pipeline by Array BioPharma Inc., H2 2016 43 Relapsed Acute Myeloid Leukemia - Pipeline by Astellas Pharma Inc., H2 2016 44 Relapsed Acute Myeloid Leukemia - Pipeline by AstraZeneca Plc, H2 2016 45 Relapsed Acute Myeloid Leukemia - Pipeline by AVEO Pharmaceuticals, Inc., H2 2016 46 Relapsed Acute Myeloid Leukemia - Pipeline by Bellicum Pharmaceuticals, Inc., H2 2016 47 Relapsed Acute Myeloid Leukemia - Pipeline by Bio-Cancer Treatment International Limited, H2 2016 48 Relapsed Acute Myeloid Leukemia - Pipeline by BioLineRx, Ltd., H2 2016 49 Relapsed Acute Myeloid Leukemia - Pipeline by BioSight Ltd., H2 2016 50 Relapsed Acute Myeloid Leukemia - Pipeline by Boehringer Ingelheim GmbH, H2 2016 51 Relapsed Acute Myeloid Leukemia - Pipeline by Boston Biomedical, Inc., H2 2016 52 Relapsed Acute Myeloid Leukemia - Pipeline by Bristol-Myers Squibb Company, H2 2016 53 Relapsed Acute Myeloid Leukemia - Pipeline by Calithera Biosciences, Inc., H2 2016 54 Relapsed Acute Myeloid Leukemia - Pipeline by Celgene Corporation, H2 2016 55 Relapsed Acute Myeloid Leukemia - Pipeline by Cornerstone Pharmaceuticals, Inc., H2 2016 56 Relapsed Acute Myeloid Leukemia - Pipeline by CSPC Pharmaceutical Group Limited, H2 2016 57 Relapsed Acute Myeloid Leukemia - Pipeline by CTI BioPharma Corp., H2 2016 58 Relapsed Acute Myeloid Leukemia - Pipeline by Daiichi Sankyo Company, Limited, H2 2016 59 Relapsed Acute Myeloid Leukemia - Pipeline by Eisai Co., Ltd., H2 2016 60 Relapsed Acute Myeloid Leukemia - Pipeline by Eli Lilly and Company, H2 2016 61 Relapsed Acute Myeloid Leukemia - Pipeline by EpiZyme, Inc., H2 2016 62 Relapsed Acute Myeloid Leukemia - Pipeline by Exelixis, Inc., H2 2016 63 Relapsed Acute Myeloid Leukemia - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 64 Relapsed Acute Myeloid Leukemia - Pipeline by FLX Bio, Inc., H2 2016 65 Relapsed Acute Myeloid Leukemia - Pipeline by FORMA Therapeutics Inc, H2 2016 66 Relapsed Acute Myeloid Leukemia - Pipeline by Fujifilm Corporation, H2 2016 67 Relapsed Acute Myeloid Leukemia - Pipeline by GlaxoSmithKline Plc, H2 2016 68 Relapsed Acute Myeloid Leukemia - Pipeline by GlycoMimetics, Inc., H2 2016 69 Relapsed Acute Myeloid Leukemia - Pipeline by Igenica Biotherapeutics, Inc., H2 2016 70 Relapsed Acute Myeloid Leukemia - Pipeline by Incyte Corporation, H2 2016 71 Relapsed Acute Myeloid Leukemia - Pipeline by JW Pharmaceutical Corporation, H2 2016 72 Relapsed Acute Myeloid Leukemia - Pipeline by Karyopharm Therapeutics, Inc., H2 2016 73 Relapsed Acute Myeloid Leukemia - Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2016 74 Relapsed Acute Myeloid Leukemia - Pipeline by MacroGenics, Inc., H2 2016 75 Relapsed Acute Myeloid Leukemia - Pipeline by Merck & Co., Inc., H2 2016 76 Relapsed Acute Myeloid Leukemia - Pipeline by Millennium Pharmaceuticals Inc, H2 2016 77 Relapsed Acute Myeloid Leukemia - Pipeline by NantKwest, Inc., H2 2016 78 Relapsed Acute Myeloid Leukemia - Pipeline by Novartis AG, H2 2016 79 Relapsed Acute Myeloid Leukemia - Pipeline by Oxford BioTherapeutics Ltd, H2 2016 80 Relapsed Acute Myeloid Leukemia - Pipeline by Pfizer Inc., H2 2016 81 Relapsed Acute Myeloid Leukemia - Pipeline by Pharma Mar, S.A., H2 2016 82 Relapsed Acute Myeloid Leukemia - Pipeline by Polaris Pharmaceuticals, Inc., H2 2016 83 Relapsed Acute Myeloid Leukemia - Pipeline by Seattle Genetics, Inc., H2 2016 84 Relapsed Acute Myeloid Leukemia - Pipeline by Sunesis Pharmaceuticals, Inc., H2 2016 85 Relapsed Acute Myeloid Leukemia - Pipeline by TaiGen Biotechnology Co., Ltd., H2 2016 86 Relapsed Acute Myeloid Leukemia - Pipeline by Teva Pharmaceutical Industries Ltd., H2 2016 87 Relapsed Acute Myeloid Leukemia - Pipeline by Tolero Pharmaceuticals, Inc., H2 2016 88 Relapsed Acute Myeloid Leukemia - Pipeline by VioQuest Pharmaceuticals, Inc., H2 2016 89 Relapsed Acute Myeloid Leukemia - Pipeline by ZIOPHARM Oncology, Inc., H2 2016 90 Assessment by Monotherapy Products, H2 2016 91 Assessment by Combination Products, H2 2016 92 Number of Products by Stage and Target, H2 2016 94 Number of Products by Stage and Mechanism of Action, H2 2016 101 Number of Products by Stage and Route of Administration, H2 2016 108 Number of Products by Stage and Molecule Type, H2 2016 110 Relapsed Acute Myeloid Leukemia - Dormant Projects, H2 2016 425 Relapsed Acute Myeloid Leukemia - Dormant Projects (Contd..1), H2 2016 426 Relapsed Acute Myeloid Leukemia - Discontinued Products, H2 2016 427
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
